nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.06.2008 | Original Paper

Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit

verfasst von: L. Dova, G. Pentheroudakis, V. Golfinopoulos, V. Malamou-Mitsi, I. Georgiou, G. Vartholomatos, A. Ntemou, G. Fountzilas, N. Pavlidis

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Aims

In view of available targeted therapies, we investigated the presence of c-kit, PDGFR gene mutations and protein expression in cancer of unknown primary (CUP) in order to study their contribution in pathogenesis, their prognostic value and potential as therapeutic targets.

Methods

Mutations in hot spots c-kit exon 11 and PDGFR exons 12 and 18 were studied in paraffin-embedded tumour samples from 50 patients with CUP by means of PCR-based single-strand conformational polymorphism and protein expression by means of streptavidin-biotin immunoperoxidase assays. Molecular markers were screened for possible correlations with patient outcome.

Results

No shifted band was detected in any of the polyacrylamide gel electrophoreses, indicating absence of c-kit exon 11 and PDGFR exon 12, 18 mutations. Immunohistochemical analysis in 37 tumours revealed positive membranous CD117 expression in 30 samples (81%) of which five exhibited strong (+3), four moderate (+2) and 21 weak (+1) staining. PDGFRa protein staining was seen in 15 out of 30 (50%) cases, mostly weak (13) and rarely moderate (1) or strong (1). The expression of KIT or PDGFRa protein did not correlate with the clinical outcome of the patients in our cohort.

Conclusions

In a moderate-sized CUP patient cohort, KIT or PDGFRa protein overexpression is rare, does not have gross prognostic significance for survival and is not associated with presence of activating mutations.

Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139–145PubMed

Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K (2003) Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39(6):793–799PubMedCrossRef

Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 7(5):R788–R795PubMedCrossRef

Claesson-Welsh L, Eriksson A, Westermark B, Heldin CH (1989) cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. Proc Natl Acad Sci USA 86(13):4917–4921PubMedCrossRef

Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22(18):3813–3825PubMedCrossRef

Corless CL, Schroeder A, Griffith D et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23(23):5357–5364PubMedCrossRef

Debiec-Rychter M, Dumez H, Judson I et al (2004) EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40(5):689–695PubMedCrossRef

Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480PubMedCrossRef

Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338PubMedCrossRef

de Silva CM, Reid R (2003) Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9(1):13–19PubMedCrossRef

Dova L, Pentheroudakis G, Georgiou I et al (2007) Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastases 24(2):79–86CrossRef

Gomes AL, Bardales RH, Milanezi F, Reis RM, Schmitt F (2007) Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 127(1):1–8

Heinrich MC, Corless CL, Duensing A et al (2003a) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708–710PubMedCrossRef

Heinrich MC, Corless CL, Demetri GD et al (2003b) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342–4349PubMedCrossRef

Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316PubMed

Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580PubMedCrossRef

Hirota S, Ohashi A, Nishida T et al (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125(3):660–667PubMedCrossRef

Johnson BE, Fischer T, Fischer B et al (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9(16 Pt 1):5880–5887PubMed

Kazlauskas A, Cooper JA (1989) Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 58(6):1121–1133PubMedCrossRef

Kitamura Y, Hirotab S (2004) Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61(23):2924–2931PubMedCrossRef

Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA et al (1996) Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 178(2):151–160PubMedCrossRef

Liegl B, Leithner A, Bauernhofer T et al (2006) Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology 49(6):576–581PubMedCrossRef

Marx J. (2005) Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science 308(5726):1248–1249PubMedCrossRef

Motzer RJ, Rini BI, Bukowski RM et al (2006a) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524PubMedCrossRef

Motzer RJ, Michaelson MD, Redman BG et al (2006a) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16–24PubMedCrossRef

Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J (2005) Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124(1):71–76PubMedCrossRef

Pentheroudakis G, Pavlidis N (2006) Perspectives for targeted therapy in cancer of unknown primary site. Cancer Treat Rev 32:637–644PubMedCrossRef

Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12(4):418–425PubMedCrossRef

Peterson MR, Piao Z, Weidner N, Yi ES (2006) Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: immunohistochemical and mutational analyses. Appl Immunohistochem Mol Morphol 14(4):390–6PubMedCrossRef

Rashid A, Hess KR, Lenzi R, et al (2005) Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). Journal of Clinical Oncology 2005, ASCO Annual Meeting Proceedings, Vol 23, No 16S, Part 1, June 1 Supplement, Abstract number 9683

Rubin BP, Singer S, Tsao C et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61(22):8118–8121PubMed

Shih AH, Holland EC (2006) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 232(2):139–147PubMedCrossRef

Sihto H, Sarlomo-Rikala M, Tynninen O et al (2005) KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 23(1):49–57PubMedCrossRef

Sulzbacher I, Birner P, Träxler M, Marberger M, Haitel A (2003a) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120(1):107–112PubMedCrossRef

Sulzbacher I, Birner P, Trieb K, Träxler M, Lang S, Chott A (2003b) Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 16(1):66–71PubMedCrossRef

Ugurel S, Hildenbrand R, Zimpfer A et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92(8):1398–1405PubMedCrossRef

Went PT, Dirnhofer S, Bundi M et al (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22(22):4514–4522PubMedCrossRef

Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS (2005) Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 36(3):242–249PubMedCrossRef

Yarden Y, Kuang WJ, Yang-Feng T et al (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6(11):3341–3351PubMed

Titel: Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit
verfasst von: L. Dova
G. Pentheroudakis
V. Golfinopoulos
V. Malamou-Mitsi
I. Georgiou
G. Vartholomatos
A. Ntemou
G. Fountzilas
N. Pavlidis
Publikationsdatum: 01.06.2008
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2008
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-007-0341-7

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit

Abstract

Aims

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine

Paclitaxel (Taxol®)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L)

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound

LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis

Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie